SillaJen, Inc.
๐ฐ๐ทSouth Korea
BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia
Phase 1
Recruiting
- Conditions
- Advanced Solid TumorTNBC - Triple-Negative Breast CancerGastric CancerLeukemia Acute Myeloid Leukemia (AML)
- Interventions
- Drug: BAL0891Combination Product: PaclitaxelCombination Product: Carboplatin
- First Posted Date
- 2023-03-15
- Last Posted Date
- 2025-04-03
- Lead Sponsor
- SillaJen, Inc.
- Target Recruit Count
- 260
- Registration Number
- NCT05768932
- Locations
- ๐บ๐ธ
Yale New Haven Hospital, New Haven, Connecticut, United States
๐บ๐ธUniversity of Miami Health System, Coral Gables, Florida, United States
๐บ๐ธMontefiore Medical Center, Bronx, New York, United States
A Study of Recombinant Vaccinia Virus in Combination With Cemiplimab for Renal Cell Carcinoma
Phase 1
Active, not recruiting
- Conditions
- Renal Cell Carcinoma
- Interventions
- Biological: Pexastimogene Devacirepvec (Pexa-Vec)Biological: Cemiplimab
- First Posted Date
- 2017-09-26
- Last Posted Date
- 2022-10-27
- Lead Sponsor
- SillaJen, Inc.
- Target Recruit Count
- 89
- Registration Number
- NCT03294083
- Locations
- ๐ฆ๐บ
Site 2632 Flinders Medical Centre, Bedford Park, Australia
๐บ๐ธSite 2643 Washington University, Saint Louis, Missouri, United States
๐ฐ๐ทSite 2612 Kyungpook National University Chilgok Hospital, Daegu, Korea, Republic of
Hepatocellular Carcinoma Study Comparing Vaccinia Virus Based Immunotherapy Plus Sorafenib vs Sorafenib Alone
Phase 3
Completed
- Conditions
- Hepatocellular Carcinoma (HCC)
- Interventions
- Biological: Pexastimogene Devacirepvec (Pexa Vec)
- First Posted Date
- 2015-09-29
- Last Posted Date
- 2020-12-16
- Lead Sponsor
- SillaJen, Inc.
- Target Recruit Count
- 459
- Registration Number
- NCT02562755
- Locations
- ๐จ๐ณ
Site No. 8306, Taichung, Taiwan
๐น๐ญSite No. 8505, Bangkok, Thailand
๐น๐ญSite No. 8503, Chiang Mai, Thailand
ยฉ Copyright 2025. All Rights Reserved by MedPath